Edgewise Therapeutics
Sarah Lehman, Ph.D., is a principal scientist at Edgewise Therapeutics with a background in muscle physiology and expertise in sarcomere biophysics. Sarah has experience in both in vitro and in vivo studies and is focused on testing and implementing therapeutic targets for muscle diseases. Prior to their current role, Sarah worked as a postdoctoral researcher and fellow at the University of Colorado, where Sarah furthered their research in this field. Sarah also served as a graduate research assistant at the University of Arizona, investigating biophysical derangements in hypertrophic cardiomyopathy. Sarah holds a Ph.D. in Physiology from the University of Arizona and a Bachelor of Science in Chemical Biology from Stevens Institute of Technology.
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.